The Fast Glycaneering process reportedly allows customized N-glycosylation to meet target profiles, specifically antibodies that harbor afucosylated humanized N-glycans (with increased ADCC) or humanized N-glycans.
Talactoferrin is in Phase III, and DSM is already on board as a producer.
Thermo Fisher Scientific has agreed to acquire Brammer Bio for $1.7 billion cash, the companies said, in a deal designed to increase the buyer’s presence in gene therapy with the viral vector contract development...
Amicus Therapeutics will address clinical and commercial supply needs for its intrathecal AAV Batten disease gene therapy programs by partnering with Thermo Fisher Scientific’s recently-acquired Brammer Bio.
908 Devices benchtop analyzer allows biopharma researchers to accelerate process-development cycles and maximize their bioreactor utilization by running media analysis at-line, anytime.
The company’s $6 million investment doubles the Alachua County Florida site’s laboratory and warehousing capacity for upstream process development and quality control testing of gene therapy products.
Sciar Company, which says its product could help manufacturers automatically log product samples and reagents and reduce the risk of errors in manual workflows, reports that the necessary applications for AR and cloud infrastructure for its software are already built but continue to be developed based on customer feedback from pilot studies.
Expert says a company seeking flexible ways of making high-value, low-volume products should try cell-free expression as the method requires minimal manufacturing infrastructure and process development requirements.
Firm claims bioengineered E. coli leads to fivefold increase in production yield of recombinant human protein.